Carsten Brunn

Chief Executive Officer, Cartesian Therapeutics

Search every verified Carsten Brunn interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Carsten Brunn, chief executive officer of Cartesian Therapeutics, previously served as president and CEO of Selecta Biosciences, where he discussed the company's ImmTOR platform and its efforts to address the immunogenicity of adeno-associated virus (AAV) vectors in gene therapy. In a January 2021 podcast appearance, Brunn noted that gene therapy had made "tremendous progress" and that AAV vectors, used primarily for in vivo applications, are "highly immunogenic," meaning patients exposed to the AAV capsid can develop high antibody titers. He also described Selecta's partnerships with AskBio, a gene therapy company founded by Jude Samulski and later acquired by Bayer for approximately four billion dollars, characterizing the relationship as involving both a straight license and other collaborative elements. Brunn also discussed manufacturing scale-up for Selecta's programs, stating that the company was already manufacturing at scale for a phase three trial and that the process had been completed, though regulatory work remained to achieve full good manufacturing practice certification from the FDA. He emphasized the importance of reproducible manufacturing to the success of the business model and expressed optimism about the year ahead, while acknowledging that the company would ultimately be judged by its data.